VMI
ITCI

VHCP Management III’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

VHCP Management III’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$19.7M Buy
+575,000
New +$6.9M 3.92% 8

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VHCP Management III's ITCI Position: Q4 2019 in Review

VHCP Management III opened a new position in Intra-Cellular Therapies Inc. (ITCI) in Q4 2019: 575,000 shares worth $19.7M. The stake represents 3.92% of the portfolio and ranks #8 among its holdings.

133 funds tracked by Wall St. Rank hold ITCI as of Q4 2019.

  • VHCP Management III held 575,000 shares of Intra-Cellular Therapies Inc. worth $19.7M as of Q4 2019.
  • Intra-Cellular Therapies Inc. was a new VHCP Management III position in Q4 2019.
  • Intra-Cellular Therapies Inc. made up 3.92% of VHCP Management III's portfolio in Q4 2019, its #8 holding.
  • 133 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q4 2019.

Based on VHCP Management III's 13F filing for Q4 2019, filed 13 Feb 2020.